Publications found:
36,694
Sort by:
European Pharmaceutical Market: Strategic Assessments of Leading Suppliers
US$ 7,840.00
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ...
September 2011
1353 pages
North American Pharmaceutical Market: Strategic Assessments of Leading Suppliers
US$ 7,840.00
... executives with strategically significant competitor information and analysis of the leading players in the North American pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. ...
September 2011
1353 pages
Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers
US$ 7,840.00
... information and analysis of the leading players in the Global Cardiovascular Drug Market. The report provides a worldwide strategic overview of the pharmaceutical ... , demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key ...
September 2011
1353 pages
Global CNS Drug Market: Strategic Assessments of Leading Suppliers
US$ 7,840.00
... product segments: ethical, OTC, generics. Sales forecast for major drug categories. Sales forecasts by geographical region: North America, Europe, Japan, ... , capabilities, goals and strategies of the leading players in the global CNS drug market. To help current suppliers realistically assess their financial ...
September 2011
1353 pages
Global Oncology Drug Market: Strategic Assessments of Leading Suppliers
US$ 7,840.00
... information and analysis of the leading players in the Global Oncology Drug Market. The report provides a worldwide strategic overview of the pharmaceutical ... economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key ...
September 2011
1353 pages
Pharmasset - Tapping Both IFN and IFN-Free Opportunities
US$ 140.00
... daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises ... NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the ... IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN ...
September 2011
7 pages
Booming Clinical Trials Market in India
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 India has billion plus population and a home for various life threate...
August 2011
145 pages
Booming Generics Drug Market in India
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 The world has witnessed a sharp increase in the demand for cost-effec...
August 2011
60 pages
Pharma Marketing Excellence: Lessons from Experience
US$ 595.00
Marketing excellence. Over the past five years, those two words have been the subject of hype and the focus of management attention. As the pharmaceutical industry struggles with market maturation and...
August 2011
45 pages
Digital Marketing Talent: Who Is Pharma hiring?
US$ 495.00
Digital technology—it's everywhere you look. And nowhere is the impact of digital technology more apparent than new digital job creations and hiring practices within the pharmaceutical industry.
...
August 2011
37 pages
DNA Sequencing: Role in Clinical Laboratories
US$ 680.00
... , detection, gene profiling, and expression, polymorphism, screening, protein interaction networks, and others. Sequencing is expected to continue playing a major role in clinical laboratories, e.g., in detecting resistance mutations in viruses and bacteria, especially because of the rising availability of ...
August 2011
15 pages
Sun Pharma- Strong Margin Indicates A Strong Product Portfolio
US$ 140.00
Sun Pharma’s Q1 FY12 result was largely in line with our ... performance was not quite upto the mark, however, EBITDA margin improved by 300 bps Q-o-Q (Y-o-Y not relevant owing to launch of ... peers in the pharma space due to its rich, highly probable and yet hidden Para IV pipeline, strong balance sheet, likely ...
August 2011
8 pages
Market Access Brazil: Unlocking Pharma Potential
US$ 795.00
With this year’s election of president Dilma Rousseff, Brazil has indicated a willingness to encourage long-term foreign investment in the pharmaceutical industry. Yet while Rousseff has set three cri...
July 2011
38 pages
The Impact of iPads on pharma: a Primer
US$ 245.00
With the launch of Apple's iPad in April 2010, the way we use technology changed forever. Instant, portable and quick, the iPad is expected to sell 50 million units in 2011 alone.
Its impact...
July 2011
33 pages
Para IV Pipeline Analysis of Indian Pharma Companies
US$ 400.00
... cliff of 2014, many of the Indian companies are choosing the Para IV route to grab a higher market share, both in value and volume ... world’s top 11 products under litigation. This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the ...
June 2011
214 pages
Global Obesity Drug Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 1,100.00 CD-ROM: US$ 1,100.00 The obesity epidemic has been disseminating among developed countries as well as low...
June 2011
85 pages
Pharma on Twitter: Developing a Presence
US$ 395.00
Does your company have a Twitter account? Want to know what all the buzz is about? Whether you are an experienced Twitter user or just curious, Pharma on Twitter: Developing a Presence, shares first-h...
June 2011
56 pages
Analyzing the Major Pharmaceutical Markets
US$ 300.00
... the knowledge employment ratios globally. Aruvian's R'search’s report – Analyzing the Major Pharmaceutical Markets - globally is a complete ready country reckoner which offers the analyst ...
June 2011
100 pages
Looking at Offshoring in the Pharmaceutical Industry
US$ 300.00
... expand their global pharmaceutical revenues. Aruvian's R'search’s report – Looking at Offshoring in the Pharmaceutical Industry - is a detailed analysis of the ... employment scenarios in emerging and growing economies. The impact of Offshoring as a practice cannot be understood without a complete study of ...
June 2011
50 pages
Competitor Analysis: Hepatitis Vaccines
US$ 498.00
... Vaccines Combination Vaccines including HAV Vaccines Combination Vaccines including HBV Vaccines Hepatitis C Virus Vaccines Hepatitis E Virus Vaccines Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...
June 2011
96 pages
Cardizem CD: Para IV For An Age Old Compound, Still Enjoys Limited Competition
US$ 350.00
Our recent study about the Cardizem CD Para IV litigation between Sun Pharma and Valeant ( ... 2012 (2) there is currently no competition for 360mg Cardizem CD and Sun Pharma will be the only generic ... Sun will be able to launch the generic of Cardizem CD upon receiving final USFDA approval including the launch ...
June 2011
3 pages
Sun Pharma's Para IV Pipeline Analysis
US$ 350.00
Sun Pharma has the pipeline of ~29 Para IVs having branded sales of ~$25b. Among its Para IV pipeline the confirmed opportunities (branded sales of ~ $7.8b) are Gleevec, Namenda, Comtan, ...
June 2011
27 pages
Clinical Trials Market in Russia
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 The clinical trials market in Russia is one of the vibrant sectors in...
May 2011
50 pages
Drug Combinations: New Rules, New Opportunities
US$ 895.00
Single symptom. Single illness. Single drug.
For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease patholo...
May 2011
48 pages
Keys for Pharma Success: Integrating Social
US$ 595.00
Pharma companies began their journey in social media over four years ago with a single initiative, often a Twitter account. Subsequently, they have embarked upon a process of layering their digital fo...
May 2011
51 pages
Competitor Analysis Influenza Vaccines
US$ 718.00
... of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...
May 2011
123 pages
Middle East and Africa Pharma Sector Forecast to 2012
US$ 1,200.00
Single User PDF Format: US$ 1,200.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,400.00
CD-ROM: US$ 1,400.00 of market defining regulations and increasing expenditure on healthca...
April 2011
80 pages
Production, Market and Benchmarking of Synthetic Vitamin E in China
US$ 14,897.00
... vitamin E producers’ competitiveness in China, CCM did production benchmarking analysis of three major vitamin E producers in China. What is the detailed ... in China in 2011? This report combines CCM’s expertise in vitamin E market research. Aspects as follows can be expected: Production situation ...
April 2011
57 pages
Bangladesh Vitamins & Minerals Market Report & Forecasts
US$ 750.00
IMARC’s new report “Bangladesh Vitamins & Minerals Market Report & Forecasts” provides an analytical and statistical insight into the Bangladesh vitamins and minerals market. The report provides both...
April 2011
147 pages
Competitor Analysis: Emerging Diabetes Drugs
US$ 870.00
Product description The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT ...
April 2011
104 pages
Russian Pharma Sector Forecast to 2013
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,200.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 The Russian pharma industry is one of the most prolific sectors in the heal...
March 2011
100 pages
Pharma Blogging: Speaking Out
US$ 495.00
Blogging offers Pharma companies the opportunity to engage with key constituencies in an informal manner, the ability to present their interpretation of stories pertaining to their organization in the...
March 2011
42 pages
Global Pharmaceutical Market Forecast to 2012
US$ 1,600.00
Single User PDF Format: US$ 1,600.00
Multi-User License: US$ 2,400.00
Hard Copy: US$ 1,800.00
CD-ROM: US$ 1,800.00 The pharmaceutical market worldwide, after experiencing a slump durin...
February 2011
190 pages
Pharma Market Insights: Closed Loop Marketing
US$ 695.00
Instant feedback. Increased customer satisfaction and accessibility. The right product to the right doctor.The potential of Closed Loop Marketing (CLM) to fulfill those promises is vast. As a strategy...
February 2011
96 pages
Top 10 Drug Delivery Technologies Market
US$ 3,390.00
... to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are: Oral drug delivery technologies Injectable drug delivery technologies Pulmonary drug delivery technologies Transdermal drug delivery technologies Other drug delivery technologies The report also ...
February 2011
388 pages
Global Injectable Drug Delivery Market (2010 - 2015)
US$ 3,390.00
... on market dynamics, increasing innovation from alternative technologies and threat from competitors in injectable drug delivery market to sustain their market position. This report highlights the global injectable drug delivery market segmented as below Injectable systems (Sustained Release Injectable Systems, Needleless Systems ...
February 2011
253 pages
Competitor Analysis: Insulin
US$ 616.00
Product description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and insulin analogs for the treatment of type 1 and type 2 diabetes mellitus. Purchase of the pdf report includes ...
January 2011
73 pages
